Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 12:00 PM ET. The webcast can be accessed on the company's website under the Investors section, and a replay will be available for 30 days. Theravance focuses on respiratory medicines, boasting FDA-approved YUPELRI® for COPD. The company is committed to developing transformative therapies to improve respiratory health.
Theravance Biopharma (NASDAQ: TBPH) will participate in the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on November 30, 2021, at 11:20 am ET. The webcast can be accessed under the Investors section on Theravance.com and will be available for 30 days afterward. The biopharmaceutical company focuses on developing respiratory medicines, including the FDA-approved YUPELRI (revefenacin) for treating COPD. The company aims to enhance patient lives through innovative respiratory therapies.
Theravance Biopharma (TBPH) reported Q3 2021 financial results, showing total revenue of $13.2 million, down $5.1 million from Q3 2020. The decrease was primarily due to reduced collaboration revenue from Janssen. YUPELRI revenue was $10.4 million, reflecting a 7% year-over-year increase. The company aims for cash-flow positivity by H2 2022, planning a 75% workforce reduction by February 2022. R&D expenses decreased to $43.7 million from $67.4 million year-over-year, while operating loss improved to $53.6 million from $76.6 million.
Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 5:00 PM ET. The call can be accessed by dialing (855) 296-9648 domestically or (920) 663-6266 internationally, using confirmation code 9772385. Company highlights include its focus on respiratory medicines and notable products like YUPELRI for COPD. Future financial benefits may arise from agreements with GSK related to certain programs.
Theravance Biopharma (NASDAQ: TBPH) announced significant strategic actions aimed at enhancing shareholder value, including a 75% workforce reduction, affecting around 270 positions, with expected completion by February 2022. The company anticipates annualized operating expense savings of approximately $165 million in 2022. Updated financial guidance projects R&D expenses to drop from $195-225 million in 2021 to $55-65 million in 2022, while SG&A expenses are expected to reduce to $30-40 million. The firm plans to focus on its respiratory therapeutic portfolio, notably YUPELRI and TRELEGY, aiming for positive cash flow in the second half of 2022.
Theravance Biopharma (NASDAQ: TBPH) announced that its Phase 3 study of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) did not meet the primary endpoint. While mild to moderate adverse events were reported, no serious side effects were attributed to the drug. The company plans to analyze the findings further and present results at a future scientific forum. CEO Rick E Winningham expressed disappointment, highlighting the unmet need for effective treatments for nOH.
Theravance Biopharma (NASDAQ: TBPH) announced disappointing top-line results from its Phase 2b induction study of izencitinib for ulcerative colitis. The study failed to meet its primary endpoint of change in total Mayo score and the secondary endpoint of clinical remission at week 8 compared to placebo. However, izencitinib was well-tolerated, showing similar adverse event rates to placebo. The company plans to further analyze the study data and upcoming results from ongoing studies, including a Crohn's Phase 2 study expected in early 2022.
Theravance Biopharma reported its Q2 2021 financial results, highlighting a total revenue of $12.9 million, a decrease of $2.1 million year-over-year. Revenue from YUPELRI collaboration with Viatris was $10.9 million, translating to a 35% share of net sales. R&D expenses reduced to $51.1 million, while SG&A expenses rose to $25.9 million. The company closed a public offering raising $115.6 million and anticipates key clinical results for its products in upcoming quarters. Cash position remains strong at $265 million.
Theravance Biopharma (NASDAQ: TBPH) will report its Q2 2021 financial results and provide a business update on August 3, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines for inflammation and immunology, aiming to enhance therapeutic effectiveness while minimizing side effects. They leverage expertise in developing lung-selective medicines, including FDA-approved YUPELRI for COPD. For more details, visit www.theravance.com.
Theravance Biopharma (NASDAQ: TBPH) has announced the pricing of its public offering of 6.7 million ordinary shares at $15.00 per share, aiming to raise approximately $100.5 million. The offering is set to close on June 29, 2021, subject to customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 1,005,000 additional shares. The offering is led by SVB Leerink and Evercore ISI. Theravance Biopharma has filed the necessary registration with the SEC and will publish a final prospectus supplement shortly.
